Emergency Contraceptives Rao 2019
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten Et Al
US00787 1995 B2 (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten et al. (45) Date of Patent: *Jan. 18, 2011 (54) DRUG DELIVERY SYSTEM COMPRISINGA (52) U.S. Cl. ....................................... 514/171; 514/182 TETRAHYDROXYLATED ESTROGEN FOR (58) Field of Classification Search ................. 514/171, USE IN HORMONAL CONTRACEPTION 514f182 See application file for complete search history. (75) Inventors: Evert Johannes Bunschoten, Heesch (NL); Herman Jan Tijmen Coelingh (56) References Cited Bennink, Driebergen (NL); Christian U.S. PATENT DOCUMENTS Franz Holinka, New York, NY (US) 3,440,320 A 4, 1969 Sackler et al. O O 3,797.494. A 3, 1974 Zaffaroni (73) Assignee: Pantarhei Bioscience B.V., Al Zeist 4,460.372 A 7/1984 Campbell et al. (NL) 4,573.996 A 3/1986 Kwiatek et al. 4,624,665 A 1 1/1986 Nuwayser (*) Notice: Subject to any disclaimer, the term of this 4,722,941 A 2f1988 Eckert et al. patent is extended or adjusted under 35 4,762,717 A 8/1988 Crowley, Jr. U.S.C. 154(b) by 1233 days. 4.937,238 A 6, 1990 Lemon 5,063,507 A 1 1/1991 Lindsey et al. This patent is Subject to a terminal dis- 5,130,137 A 7/1992 Crowley, Jr. claimer. 5,211,952 A 5/1993 Spicer et al. 5,223,261 A 6/1993 Nelson et al. 5,340,584 A 8/1994 Spicer et al. (21) Appl. No.: 10/478,357 5,340,585 A 8/1994 Pike et al. 1-1. 5,340,586 A 8, 1994 Pike et al. -
Mifepristone
1. NAME OF THE MEDICINAL PRODUCT Mifegyne 200 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200-mg mifepristone. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet. Light yellow, cylindrical, bi-convex tablets, with a diameter of 11 mm with “167 B” engraved on one side. 4. CLINICAL PARTICULARS For termination of pregnancy, the anti-progesterone mifepristone and the prostaglandin analogue can only be prescribed and administered in accordance with New Zealand’s abortion laws and regulations. 4.1 Therapeutic indications 1- Medical termination of developing intra-uterine pregnancy. In sequential use with a prostaglandin analogue, up to 63 days of amenorrhea (see section 4.2). 2- Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester. 3- Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester). 4- Labour induction in fetal death in utero. In patients where prostaglandin or oxytocin cannot be used. 4.2 Dose and Method of Administration Dose 1- Medical termination of developing intra-uterine pregnancy The method of administration will be as follows: • Up to 49 days of amenorrhea: 1 Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of the prostaglandin analogue: misoprostol 400 µg orally or per vaginum. • Between 50-63 days of amenorrhea Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of misoprostol. -
(12) United States Patent (10) Patent No.: US 7,723,320 B2 Bunschoten Et Al
US007723320B2 (12) United States Patent (10) Patent No.: US 7,723,320 B2 Bunschoten et al. (45) Date of Patent: May 25, 2010 (54) USE OF ESTROGEN COMPOUNDS TO DE 23,36434. A 4, 1975 INCREASE LIBDO IN WOMEN WO WO96 O3929 A 2, 1996 (75) Inventors: Evert Johannes Bunschoten, Heesch OTHER PUBLICATIONS (NL); Herman Jan Tijmen Coelingh Bennink, Driebergen (NL); Christian Holinka CF et al: “Comparison of Effects of Estetrol and Taxoxifen Franz Holinka, New York, NY (US) with Those of Estriol and Estradiol on the Immature Rat Uterus'; Biology of Reproduction; 1980; pp. 913-926; vol. 22, No. 4. (73) Assignee: Pantarhei Bioscience B.V., Al Zeist Holinka CF et al; "In-Vivo Effects of Estetrol on the Immature Rat (NL) Uterus'; Biology of Reproduction; 1979: pp. 242-246; vol. 20, No. 2. Albertazzi Paola et al.; "The Effect of Tibolone Versus Continuous Combined Norethisterone Acetate and Oestradiol on Memory, (*) Notice: Subject to any disclaimer, the term of this Libido and Mood of Postmenopausal Women: A pilot study': Data patent is extended or adjusted under 35 base Biosis "Online!; Oct. 31, 2000: pp. 223-229; vol. 36, No. 3; U.S.C. 154(b) by 1072 days. Biosciences Information Service.: Philadelphia, PA, US. Visser et al., “In vitro effects of estetrol on receptor binding, drug (21) Appl. No.: 10/478,264 targets and human liver cell metabolism.” Climacteric (2008) 11(1) Appx. II: 1-5. (22) PCT Filed: May 17, 2002 Visser et al., “First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.” Climacteric (2008) 11(1): (86). -
ESTROSTEP Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*) *Ferrous Fumarate Tablets Are Not USP for Dissolution and Assay
ESTROSTEP Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*) *Ferrous fumarate tablets are not USP for dissolution and assay. ESTROSTEP® Fe (Each white triangular tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol; each white square tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; each white round tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol; each brown tablet contains 75 mg ferrous fumarate.) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION ESTROSTEP® Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. ESTROSTEP Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each white triangle-shaped tablet contains 1 mg norethindrone acetate [(17 alpha)-17- (acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19- norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each white square-shaped tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each white round tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each tablet also contains calcium stearate; lactose; microcrystalline cellulose; and starch. The structural formulas are as follows: Each brown tablet contains ferrous fumarate, mannitol, povidone, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sucralose and spearmint flavor. -
Emergency Contraception
Need more information? State of Illinois This document provides some very basic information about emergency Illinois Department of Public Health contraception and how it works. If EC is something you want to know more about, ask the hospital emergency personnel about their policy on EC or ask the sexual assault advocate for assistance in getting this information. Local Support/Assistance: What You Should Know About Emergency Contraception For more information, contact ILLINOIS DEPARTMENT OF PUBLIC HEALTH 535 W. Jefferson St. Springfield, IL 62761 217-782-5750 Women’s Health-line 888-522-1282 TTY (hearing impaired use only) 800-547-0466 www.idph.state.il.us Developed by the Illinois Department of Public Health in cooperation with the Illinois Coalition Against Sexual Assault Printed by Authority of the State of Illinois IOCI 0041-1 Illinois law provides that victims of sexual assault are entitled to If I am already pregnant, medically and factually accurate information about emergency contra - ception (EC) when they receive emergency care in a hospital. Under will EC hurt the fetus? the Sexual Assault Survivors Emergency Treatment Act (410 ILCS There is no evidence that EC causes birth defects. However, there 70/2.2), Illinois hospitals are required to have a policy in place regarding have been no studies specific to taking birth control at this dosage. emergency contraception. Individual hospital protocols must ensure What is known is that babies born to women who continue taking that each victim of sexual assault will receive medically and factually birth control pills before finding out they are pregnant do not have accurate written and oral information about emergency contraception; higher rates of birth defects. -
Emergency Contraception: History, Methods, Mechanisms, Misconceptions and a Philosophical Evaluation
logy & Ob o st ec e tr n i y c s G Gynecology & Obstetrics Goldstuck, Gynecol Obstet (Sunnyvale) 2014, 4:5 DOI: 10.4172/2161-0932.1000224 ISSN: 2161-0932 Review Article Open Access Emergency Contraception: History, Methods, Mechanisms, Misconceptions and a Philosophical Evaluation Norman D Goldstuck* Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town 7505, South Africa *Corresponding author: Norman D Goldstuck, Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town 7505, South Africa, Tel: +27823418200; E-mail: [email protected] Received: Apr 07, 2014; Accepted: May 28, 2014; Published: May 31, 2014 Copyright: © 2014 Goldstuck. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Humans have attempted to disrupt the progression of pregnancy for a very long time. This dates back to the realization that it was a sexual activity which started the reproductive cycle. Folk methods for preventing pregnancy after unprotected sexual activity are physiologically unable to be effective and we now have chemical, mainly hormonal methods, and a mechanical method the intrauterine device which do work in the very early stages before conception can be diagnosed with certainty. These methods are impeded by those who worry that fertilisation of the ovum may have occurred, and that the method may then be abortifacient. Considering that it is possible to easily disrupt an established pregnancy by medical or surgical means depending on the duration, this would be no different than any other means of abortion induction. -
ARANELLE- Norethindrone and Ethinyl Estradiol Teva Pharmaceuticals USA, Inc
ARANELLE- norethindrone and ethinyl estradiol Teva Pharmaceuticals USA, Inc. ---------- Aranelle®(norethindrone and ethinyl estradiol tablets USP) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION Aranelle® 28-Day Regimen (norethindrone and ethinyl estradiol tablets USP) provides a continuous oral contraceptive regimen of 7 light yellow tablets, 9 white tablets, 5 more light yellow tablets, and then 7 peach tablets. Each light yellow tablet contains norethindrone, USP 0.5 mg and ethinyl estradiol, USP 0.035 mg, each white tablet contains norethindrone, USP 1 mg and ethinyl estradiol, USP 0.035 mg, and each peach tablet contains inert ingredients. Norethindrone, USP is a potent progestational agent with the chemical name 17- Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one. Ethinyl estradiol, USP is an estrogen with the chemical name 19-Nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. Their structural formulae follow. Norethindrone, USP Ethinyl Estradiol, USP The light yellow tablet contains the following inactive ingredients, D&C yellow no. 10 aluminum lake, lactose monohydrate, magnesium stearate, and pregelatinized starch. The white tablet contains the following inactive ingredients, lactose monohydrate, magnesium stearate, and pregelatinized starch. The inactive peach tablets contain the following inactive ingredients, anhydrous lactose, FD&C yellow no. 6 aluminum lake, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotrophins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which may reduce the likelihood of implantation). -
Gynaecology-Changing-Services-For-Changing
GYNAECOLOGY GYNAECOLOGY Changing Services for Changing Needs Edited by SUE JOLLEY Copyright © 2006 John Wiley & Sons Ltd The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777 Email (for orders and customer service enquiries): [email protected] Visit our Home Page on www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [email protected], or faxed to (+44) 1243 770620. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. -
Emergency Contraception
AQ FREQUENTLY ASKED QUESTIONS FAQ114 fCONTRACEPTION Emergency Contraception • What is emergency contraception? • How does emergency contraception work? • What are the different types of emergency contraception? • What is the most effective form of emergency contraception? • How does the copper intrauterine device work? • What are the possible side effects of using the copper intrauterine device? • How do emergency contraception pills work? • How often can I use emergency contraception pills? • What are the possible side effects of taking emergency contraception pills? • Is there anything that decreases the effectiveness of emergency contraception pills? • How can I get emergency contraception as soon as possible? • How do I start or resume using a birth control method after taking emergency contraception pills? • Do I need follow-up care after using emergency contraception? • Glossary What is emergency contraception? Emergency contraception (EC) reduces the chance of pregnancy after unprotected sexual intercourse. Common situations in which EC could be used include forgetting to take several birth control pills in a row, having a condom break or slip off, or not using a birth control method during sex. It also can be used after a woman has been raped. How does emergency contraception work? Using EC does not cause an abortion. An abortion ends an existing pregnancy. EC prevents pregnancy from occurring. EC must be used soon after unprotected sexual intercourse to be effective. It does not work if pregnancy has already occurred. What are the different types of emergency contraception? There are two main types of EC: 1) the copper intrauterine device (IUD) and 2) EC pills. There are three types of EC pills: 1) ulipristal, 2) progestin-only pills, and 3) combined EC pills. -
Emergency Contraception Krishna K
POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children Emergency Contraception Krishna K. Upadhya, MD, MPH, FAAP, COMMITTEE ON ADOLESCENCE Despite significant declines over the past 2 decades, the United States abstract continues to experience birth rates among teenagers that are significantly higher than other high-income nations. Use of emergency contraception (EC) within 120 hours after unprotected or underprotected intercourse can reduce the risk of pregnancy. Emergency contraceptive methods include oral Children’s National Health System, Washington, District of Columbia medications labeled and dedicated for use as EC by the US Food and Drug Policy statements from the American Academy of Pediatrics benefit Administration (ulipristal and levonorgestrel), the “off-label” use of combined from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American oral contraceptives, and insertion of a copper intrauterine device. Indications Academy of Pediatrics may not reflect the views of the liaisons or the for the use of EC include intercourse without use of contraception; condom organizations or government agencies that they represent. breakage or slippage; missed or late doses of contraceptives, including the Dr Upadhya was responsible for all aspects of revising and writing the policy statement with input from reviewers and the Board of Directors; oral contraceptive pill, contraceptive patch, contraceptive ring, and injectable she approves the final manuscript as submitted. contraception; vomiting after use of oral contraceptives; and sexual assault. The guidance in this statement does not indicate an exclusive course Our aim in this updated policy statement is to (1) educate pediatricians and of treatment or serve as a standard of medical care. -
Selective Progesterone Receptor Modulators in Gynaecological Therapies
65 1 Journal of Molecular H O D Critchley and SPRMs in gynaecological 65:1 T15–T33 Endocrinology R Chodankar therapies THEMATIC REVIEW 90 YEARS OF PROGESTERONE Selective progesterone receptor modulators in gynaecological therapies H O D Critchley and R R Chodankar MRC Centre for Reproductive Health, The University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh Bioquarter, Edinburgh, UK Correspondence should be addressed to H O D Critchley: [email protected] This review forms part of a special section on 90 years of progesterone. The guest editors for this section are Dr Simak Ali, Imperial College London, UK, and Dr Bert W O’Malley, Baylor College of Medicine, USA. Abstract Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition Key Words affecting one in four women of reproductive age. Current treatments (conservative, f abnormal uterine medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. bleeding (AUB) Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated f heavy menstrual bleeding (HMB) pathways, a hormone critical to female reproductive health and disease; therefore, f selective progesterone SPRMs hold great potential in fulfilling an unmet need in managing gynaecological receptor modulators disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed (SPRM) for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB f leiomyoma in women with leiomyomas and in a higher dose as an emergency contraceptive. In this f fibroid article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women’s quality of life. -
Appendix Some Important Pharmacological Agents
Appendix Some important pharmacological agents Students may feel overwhelmed by the number of drugs pharmacists play a crucial role) grapple with choosing described in pharmacology textbooks. We would empha- which individual drugs to stock in the pharmacy. There sise that it is more important to understand general phar- is a play-off between stocking several individual drugs macological principles, and to appreciate the pharmacology of one category, for each of which there is good evidence of the main classes of drug, than to attempt to memorise of efficacy for distinct indications, and stocking a more details of individual agents. Specific drugs are best learned restricted choice based on indirect evidence that efficacy about when they are encountered in the setting of particu- is likely to be a common feature of different members of lar topics (e.g. noradrenergic transmission), during practi- a class of drugs. Local variations will be encountered (e.g. cal classes or (for therapeutic drugs) near a patient’s as to which angiotensin-converting enzyme inhibitor or bedside. We provide a list (www.studentconsult.com) of non-steroidal anti-inflammatory drugs are stocked in the examples of some of the most important pharmacological hospital pharmacy). If the student or clinician (e.g. doctor, agents. It is not intended as a starting point to learning dentist, veterinarian or nurse) comes to these (e.g. when pharmacology, and we would caution against attempting changing to a job in a new hospital) with a sound appre- to memorise lists of names and properties. The important ciation of the general principles of pharmacology and of agents we list here were selected subjectively; they include the specifics of the various classes of agent involved, he or (but are not limited to) the 100 drugs most likely to be she will be able to look up and understand the details of prescribed by newly qualified doctors in the UK Baker( agents favoured locally and use them sensibly.